ProCE Banner Activity

CE / CME

Updates on CLL/SLL Care: Expert Guidance for the Multidisciplinary Teams in Veterans Health Administration Systems

Video

This on-demand webcast highlights expert guidance on optimal treatment strategies in the clinical management of patients with CLL/SLL in Veterans Health Administration systems.

Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

Released: December 01, 2023

Expiration: November 30, 2024

Share

Faculty

Solomon Graf

Solomon Graf, MD

Associate Professor
Division of Medical Oncology
University of Washington Medicine
Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director
Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Target Audience

This program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for veterans with CLL.

Program Learning Goal

This activity aims to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to optimally integrate the use of currently available therapies for their patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference

  • Develop treatment plans to address unique clinical challenges based on the available evidence and the recommendations outlined in recognized guidelines to optimize outcomes for veterans with CLL/SLL

  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles among agents with a similar molecular target used to treat CLL/SLL

  • Evaluate the evolving role of noncovalent BTK inhibitors, measurable/minimal residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy in the therapeutic strategy for veterans with CLL

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Solomon Graf, MD

Associate Professor
Division of Medical Oncology
University of Washington Medicine
Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Solomon Graf, MD: researcher: Acerta Pharma, BeiGene, GlaxoSmithKline, MorphoSys, TG Therapeutics. 

Jeffrey P. Sharman, MD

Medical Director
Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 01, 2023, through November 30, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-312-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.